0 false false false false false false false false false true false false false false false false No description of principal activity 2022-04-01 Sage Accounts Production Advanced 2021 - FRS102_2021 xbrli:pure xbrli:shares iso4217:GBP SC584289 2022-04-01 2023-03-31 SC584289 2023-03-31 SC584289 2022-03-31 SC584289 bus:Director1 2022-04-01 2023-03-31 SC584289 core:WithinOneYear 2023-03-31 SC584289 core:WithinOneYear 2022-03-31 SC584289 core:ShareCapital 2023-03-31 SC584289 core:ShareCapital 2022-03-31 SC584289 core:RetainedEarningsAccumulatedLosses 2023-03-31 SC584289 core:RetainedEarningsAccumulatedLosses 2022-03-31 SC584289 bus:SmallEntities 2022-04-01 2023-03-31 SC584289 bus:AuditExemptWithAccountantsReport 2022-04-01 2023-03-31 SC584289 bus:FullAccounts 2022-04-01 2023-03-31 SC584289 bus:SmallCompaniesRegimeForAccounts 2022-04-01 2023-03-31 SC584289 bus:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31
COMPANY REGISTRATION NUMBER: SC584289
Karma Cardiology Limited
Filleted Unaudited Financial Statements
For the year ended
31 March 2023
Karma Cardiology Limited
Statement of Financial Position
31 March 2023
2023
2022
Note
£
£
Current assets
Debtors
4
25
Cash at bank and in hand
9,454
10,589
-------
--------
9,454
10,614
Creditors: amounts falling due within one year
5
40
840
-------
--------
Net current assets
9,414
9,774
-------
-------
Total assets less current liabilities
9,414
9,774
-------
-------
Net assets
9,414
9,774
-------
-------
Capital and reserves
Called up share capital
100
100
Profit and loss account
9,314
9,674
-------
-------
Shareholder funds
9,414
9,774
-------
-------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 31 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 10 October 2023 , and are signed on behalf of the board by:
Dr K J Williams
Director
Company registration number: SC584289
Karma Cardiology Limited
Notes to the Financial Statements
Year ended 31 March 2023
1. General information
The company is a private company limited by shares, registered in Scotland. The address of the registered office is 33 Kittoch Street, Village, East Kilbride, G74 4JW, Scotland.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Consolidation
The company has taken advantage of the option not to prepare consolidated financial statements contained in Section 398 of the Companies Act 2006 on the basis that the company and its subsidiary undertakings comprise a small group.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
4. Debtors
2023
2022
£
£
Other debtors
25
----
----
5. Creditors: amounts falling due within one year
2023
2022
£
£
Other creditors
40
840
----
----
6. Controlling party
The company's ultimate parent undertaking at the statement of financial position date was KJW Clinical Research Limited , a company incorporated in Scotland.